Zevalin works as initial therapy for follicular non-Hodgkin lymphoma

01/24/2013 | Medscape (free registration)

Initial treatment with the radioimmunotherapy Zevalin, also called 90-yttrium ibritumomab tiuxetan, allowed 35% of 59 patients with follicular non-Hodgkin lymphoma to have long-lasting responses, according to a study published in the Journal of Clinical Oncology. Patients' overall response rate at six months was 86%, and 41% of patients showed complete response. "In our opinion, radioimmunotherapy is a particularly attractive therapy for older patients, patients with significant comorbidity, or patients who refuse chemotherapy," researchers said.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Corporate Life Sciences Lawyer (3-5 years exp)
Ropes & Gray LLP
Boston, MA; San Francisco, CA; Silicon Valley, CA, MA
Director of Accreditation
Meridian Health Plan
Detroit, MI
Health Services Researcher
AARP
Washington, DC
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC